Monday
07.22.2019
7:16 PM
Login form
Search
Calendar
Entries archive

My site

Main » 2015 » March » 21

Third phase III study with OTEZLA to demonstrate statistically significant improvements versus placebo for the primary and key secondary endpoints at week 16

SUMMIT, N.J. - Saturday, March 21st 2015 [ME NewsWire]

More patients achieved a PASI-75 response at week 32 than at week 16 for those randomized to OTEZLA at baseline and those switched from etanercept to OTEZLA at week 16

In a post-hoc analysis of PASI-75 at week 16, there was no statistically significant difference between OTEZLA and etanercept

No new safety signals identified through week 32 for OTEZLA

(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis were presented at a late-breaker presentation at the 73rd Annual Meeting of the American Academy of ... Read more »

Views: 99 | Added by: uaeonlinenews | Date: 03.21.2015